Two writers share their verdict on weight-loss pills vs jabs
The weight-loss race ramped up this summer as two new tablet formats from the makers of Ozempic and Mounjaro hit the market.
TL;DR
- Novo Nordisk released the Wegovy pill in July, and Eli Lilly released the Foundayo tablet two weeks later.
- Both pills are presented as more convenient and cheaper alternatives to the injectable forms of weight-loss drugs like Ozempic and Mounjaro.
- One writer experienced increased hunger, nausea, and weight gain on the Wegovy pill, despite a history of success with Mounjaro injections.
- This writer found Foundayo to have fewer side effects than Wegovy but still experienced hunger, with the long-term results pending.
- The other writer suffered severe gastrointestinal symptoms, weight gain, and fatigue on the Wegovy pill, leading her to abandon it and return to Mounjaro injections.
- The article highlights that individuals react differently to these medications, with some benefiting more from pills and others from injections.
- Foundayo is noted to be pharmacologically more similar to the Wegovy pill than to Mounjaro.
- The accessibility and ease of use of the pill formats are major advantages for those who dislike injections.